Ying Huang | BiotechTV

top of page

ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future...

Company News

Dec 9, 2024

Legend Biotech's CEO Ying Huang on moving CARVYKTI into earlier lines of treatment in the E.U. and U.S.

Ying Huang talks about Friday's CHMP positive opinion and the upcoming FDA advisory committee meeting, and highlight's Legend's pipeline.

Company News

Feb 26, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page

ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more

Legend Biotech's CEO Ying Huang on moving CARVYKTI into earlier lines of treatment in the E.U. and U.S.

Follow BiotechTV

Sponsors

Sponsor Spotlight